Do you offer somatostatin analogues (eg lanreotide, octreotide) to asymptomatic patients with metastatic, nonfunctioning, well-differentiated enteropancreatic neuroendrocrine tumors?
Given the variable and sometimes indolent disease course of these patients, as well as the absence of a clear overall survival benefit in the PROMID and CLARINET trials, how do you decide when to treat?
1 Answer
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
I do use SSA in non-functional NET because of the clear PFS benefit observed. There is a difference between whether a drug may have OS benefit in a particular setting vs whether it is possible to demonstrate it in a clinical trial. Please see our position paper:
Join for free or sign in to see the full answer